RESUMEN
Induction of severe inflammatory arthritis in the collagen antibody-induced arthritis (CAIA) murine model causes extensive joint damage and pain-like behavior compromising analysis. While mild models are less severe, their reduced, variable penetrance makes assessment of treatment efficacy difficult. This study aimed to compare macroscopic and microscopic changes in the paws, along with central nervous system activation between a mild and moderate CAIA model. Balb/c mice (n=18) were allocated to control, mild, and moderate CAIA groups. Paw inflammation, bone volume (BV), and paw volume (PV) were assessed. Histologically, the front paws were assessed for joint inflammation, cartilage damage, and pre/osteoclast-like cells and the lumbar spinal cord and the periaqueductal gray (PAG) region of the brain for glial reactivity. A moderate CAIA dose induced (1) significantly greater local paw inflammation, inflammatory cell infiltration, and PV; (2) significantly more osteoclast-like cells on the bone surface and within the surrounding soft tissue; and (3) significantly greater glial reactivity within the PAG compared with the mild CAIA model. These findings support the use of a moderate CAIA model (higher dose of monoclonal antibodies with low-dose lipopolysaccharide) to induce more consistent histopathological features, without excessive joint destruction.
Asunto(s)
Artritis Experimental/patología , Resorción Ósea/patología , Cartílago Articular/patología , Modelos Animales de Enfermedad , Edema/patología , Animales , Anticuerpos Monoclonales/administración & dosificación , Artritis Experimental/inducido químicamente , Artritis Experimental/diagnóstico , Artritis Reumatoide/diagnóstico , Artritis Reumatoide/patología , Resorción Ósea/inducido químicamente , Resorción Ósea/diagnóstico , Cartílago Articular/efectos de los fármacos , Edema/inducido químicamente , Edema/diagnóstico , Femenino , Miembro Anterior/efectos de los fármacos , Miembro Anterior/patología , Histocitoquímica , Lipopolisacáridos/administración & dosificación , Ratones , Ratones Endogámicos BALB C , Neuroglía/efectos de los fármacos , Neuroglía/patología , Osteoclastos/efectos de los fármacos , Osteoclastos/patología , Sustancia Gris Periacueductal/efectos de los fármacos , Sustancia Gris Periacueductal/patología , Índice de Severidad de la Enfermedad , Médula Espinal/efectos de los fármacos , Médula Espinal/patologíaRESUMEN
Coordination of four-limb movements during quadrupedal locomotion is controlled by supraspinal monoaminergic descending pathways, among which serotoninergic ones play a crucial role. Here we investigated the locomotor pattern during recovery from blockade of 5-HT7 or 5-HT2A receptors after intrathecal application of SB269970 or cyproheptadine in adult rats with chronic intrathecal cannula implanted in the lumbar spinal cord. The interlimb coordination was investigated based on electromyographic activity recorded from selected fore- and hindlimb muscles during rat locomotion on a treadmill. In the time of recovery after hindlimb transient paralysis, we noticed a presence of an unusual pattern of quadrupedal locomotion characterized by a doubling of forelimb stepping in relation to unaffected hindlimb stepping (2FL-1HL) after blockade of 5-HT7 receptors but not after blockade of 5-HT2A receptors. The 2FL-1HL pattern, although transient, was observed as a stable form of fore-hindlimb coupling during quadrupedal locomotion. We suggest that modulation of the 5-HT7 receptors on interneurons located in lamina VII with ascending projections to the forelimb spinal network can be responsible for the 2FL-1HL locomotor pattern. In support, our immunohistochemical analysis of the lumbar spinal cord demonstrated the presence of the 5-HT7 immunoreactive cells in the lamina VII, which were rarely 5-HT2A immunoreactive.
Asunto(s)
Locomoción/genética , Receptor de Serotonina 5-HT2A/genética , Receptores de Serotonina/genética , Traumatismos de la Médula Espinal/genética , Animales , Ciproheptadina/farmacología , Estimulación Eléctrica , Electromiografía , Miembro Anterior/efectos de los fármacos , Miembro Anterior/fisiopatología , Miembro Posterior/efectos de los fármacos , Miembro Posterior/fisiopatología , Humanos , Locomoción/efectos de los fármacos , Región Lumbosacra/fisiopatología , Ratas , Receptor de Serotonina 5-HT2A/efectos de los fármacos , Receptores de Serotonina/efectos de los fármacos , Serotonina/genética , Serotonina/metabolismo , Antagonistas del Receptor de Serotonina 5-HT2/farmacología , Médula Espinal , Traumatismos de la Médula Espinal/tratamiento farmacológico , Traumatismos de la Médula Espinal/patología , Columna Vertebral/efectos de los fármacos , Columna Vertebral/fisiopatologíaRESUMEN
Serotonergic agents can improve the recovery of motor ability after a spinal cord injury. Herein, we compare the effects of buspirone, a 5-HT1A receptor partial agonist, to fluoxetine, a selective serotonin reuptake inhibitor, on forelimb motor function recovery after a C4 bilateral dorsal funiculi crush in adult female rats. After injury, single pellet reaching performance and forelimb muscle activity decreased in all rats. From 1 to 6 weeks after injury, rats were tested on these tasks with and without buspirone (1-2 mg/kg) or fluoxetine (1-5 mg/kg). Reaching and grasping success rates of buspirone-treated rats improved rapidly within 2 weeks after injury and plateaued over the next 4 weeks of testing. Electromyography (EMG) from selected muscles in the dominant forelimb showed that buspirone-treated animals used new reaching strategies to achieve success after the injury. However, forelimb performance dramatically decreased within 2 weeks of buspirone withdrawal. In contrast, fluoxetine treatment resulted in a more progressive rate of improvement in forelimb performance over 8 weeks after injury. Neither buspirone nor fluoxetine significantly improved quadrupedal locomotion on the horizontal ladder test. The improved accuracy of reaching and grasping, patterns of muscle activity, and increased excitability of spinal motor-evoked potentials after buspirone administration reflect extensive reorganization of connectivity within and between supraspinal and spinal sensory-motor netxcopy works. Thus, both serotonergic drugs, buspirone and fluoxetine, neuromodulated these networks to physiological states that enabled markedly improved forelimb function after cervical spinal cord injury.
Asunto(s)
Médula Cervical/lesiones , Miembro Anterior/efectos de los fármacos , Recuperación de la Función/efectos de los fármacos , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Agonistas de Receptores de Serotonina/uso terapéutico , Traumatismos de la Médula Espinal/tratamiento farmacológico , Animales , Buspirona/farmacología , Buspirona/uso terapéutico , Electromiografía/efectos de los fármacos , Electromiografía/métodos , Potenciales Evocados Motores/efectos de los fármacos , Potenciales Evocados Motores/fisiología , Femenino , Fluoxetina/farmacología , Fluoxetina/uso terapéutico , Miembro Anterior/inervación , Miembro Anterior/fisiología , Fuerza de la Mano/fisiología , Ratas , Ratas Long-Evans , Recuperación de la Función/fisiología , Agonistas de Receptores de Serotonina/farmacología , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Traumatismos de la Médula Espinal/fisiopatologíaRESUMEN
BACKGROUND Parkinson disease is characterized by the loss of neurons in the substantia nigra, and under pathological conditions, glutamate can produce excitotoxic effects on nerve cells. The astrocytic excitatory amino acid transporter (EAAT) 1 can be functionally upregulated and targeted to functional compartments, resulting in reduced excitotoxicity. levodopa is the gold standard for the treatment of Parkinson disease, but prolonged levodopa treatment often leads to the development of abnormal involuntary movements. Numerous studies suggest the potential beneficial effects of traditional Chinese medicine on Parkinson disease. MATERIAL AND METHODS We validated the efficacy of a Bushen Zhichan recipe combined with levodopa in a rodent Parkinson disease model and explored its possible mechanisms. RESULTS Rats in the combined levodopa and Bushen Zhichan recipe group performed significantly better than the control group in the open field and forelimb function experiments. The number of midbrain dopaminergic neurons in rats in the levodopa and Bushen Zhichan recipe group was greater compared to controls. The levodopa and Bushen Zhichan recipe group exhibited decreased glutamate receptors and increased γ-aminobutyric acid receptors in the striatum. At the same time, EAAT1 was increased and EAAT2 was synchronized with the number of glutamate receptors. CONCLUSIONS Our results indicate that levodopa combined with Bushen Zhichan recipe significantly improves behavior and protects dopaminergic neurons in a rodent Parkinson disease model, and suggest that the mechanism involves the decrease of excitatory amino acid toxicity and the increase in the expression of EAAT1.
Asunto(s)
Cuerpo Estriado/efectos de los fármacos , Neuronas Dopaminérgicas/efectos de los fármacos , Medicamentos Herbarios Chinos/farmacología , Miembro Anterior/efectos de los fármacos , Levodopa/farmacología , Mesencéfalo/efectos de los fármacos , Trastornos Parkinsonianos/fisiopatología , Animales , Conducta Animal/efectos de los fármacos , Cistanche , Cornus , Cuerpo Estriado/metabolismo , Cuerpo Estriado/patología , Dioscorea , Modelos Animales de Enfermedad , Neuronas Dopaminérgicas/metabolismo , Neuronas Dopaminérgicas/patología , Transportador 1 de Aminoácidos Excitadores/efectos de los fármacos , Transportador 1 de Aminoácidos Excitadores/metabolismo , Transportador 2 de Aminoácidos Excitadores/efectos de los fármacos , Transportador 2 de Aminoácidos Excitadores/metabolismo , Fallopia multiflora , Miembro Anterior/fisiopatología , Haz Prosencefálico Medial , Mesencéfalo/metabolismo , Mesencéfalo/patología , Prueba de Campo Abierto/efectos de los fármacos , Oxidopamina/toxicidad , Enfermedad de Parkinson/fisiopatología , Ratas , RehmanniaRESUMEN
We performed optogenetic inactivation of rats' entopeduncular nucleus (EP, homologous to primates' globus pallidus interna (GPi)) and investigated the therapeutic effect in a rat model of PD. 6-Hydroxydopamine (6-OHDA)-induced hemiparkinsonian rats were injected with either a virus for halorhodopsin expression that is used to inactivate GABAergic neurons or a control virus injection and received optic fiber insertion. All the rats were illuminated by 590â¯nm of light. Each rat was then subjected to sequential sessions of stepping tests under controlled illumination patterns. The stepping test is a reliable evaluation method for forelimb akinesia. The number of adjusting steps was significantly higher in experimental (optogene with reporter gene expression) (5Hzâ¯-â¯10ms: 15.7⯱â¯1.9, 5Hzâ¯-â¯100ms: 16.0⯱â¯1.8, continuous: 21.6⯱â¯1.9) than control rats (reporter gene expression) (5Hz-10ms: 1.9⯱â¯1.1, 5Hz-100ms: 2.6⯱â¯1.0, continuous: 2.5⯱â¯1.2) (p < 0.001). Continuous EP illumination showed a significantly higher improvement of forelimb akinesia than other illumination patterns (p < 0.01). Optogene expression in the GABAergic neurons of the EP was confirmed by immunohistochemistry. Optogenetic inhibition of EP was effective to improve contralateral forelimb akinesia. However, further studies using prolonged illumination are needed to investigate the best illumination pattern for optogenetic stimulation.
Asunto(s)
Núcleo Entopeduncular/metabolismo , Músculo Esquelético/efectos de los fármacos , Enfermedad de Parkinson/metabolismo , Animales , Encéfalo/efectos de los fármacos , Estimulación Encefálica Profunda/métodos , Modelos Animales de Enfermedad , Núcleo Entopeduncular/fisiología , Miembro Anterior/efectos de los fármacos , Neuronas GABAérgicas/efectos de los fármacos , Neuronas GABAérgicas/metabolismo , Globo Pálido , Masculino , Músculo Esquelético/fisiología , Optogenética/métodos , Oxidopamina/farmacología , Enfermedad de Parkinson/fisiopatología , Enfermedad de Parkinson/terapia , Ratas , Ratas Wistar , Sustancia Negra/efectos de los fármacos , Núcleo Subtalámico/efectos de los fármacosRESUMEN
Ischemic stroke accounts for 70-80% of stroke cases worldwide and survivors are frequently left with compromising sensorimotor deficits localized to one or more body regions. Most animal models of stroke involve transient or permanent occlusion of one or more major vessels such as the middle cerebral artery and are characterized by widespread damage to cortical and subcortical structures that result in deficits that can confound studies of neuroprotection and neurorehabilitation. Localized microinjections of the vasoconstricting peptide endothelin-1 (ET-1) into specific brain regions are becoming increasingly popular for such studies, but the pharmacology of endothelin-induced ischemic damage is poorly understood. To test the hypothesis that NMDA receptors, and particularly those containing the NR2B subunit, are involved in ET-1-mediated excitotoxicity and functional impairment, male CD1 rats (N = 32) were pre-treated with either the non-competitive NMDA antagonist MK-801 or the NR2B-selective antagonist Ro25-6981 (or vehicle) prior to unilateral microinjections of endothelin-1 into the somatosensory cortex and striatum. Rats were then tested using 4 established tests of sensory and/or motor function over 14 days. Lesion volumes were quantified post-mortem using standard histology and image analysis. Results confirmed reproducible lesions and significant deficits in all tests in vehicle-treated rats that were significantly reduced in both drug groups but were not different between drugs, providing evidence that endothelin-induced ischemic damage is mediated almost exclusively by NR2B-containing NMDA receptors.
Asunto(s)
Isquemia Encefálica/inducido químicamente , Endotelina-1/toxicidad , Desempeño Psicomotor/efectos de los fármacos , Desempeño Psicomotor/fisiología , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , Receptores de N-Metil-D-Aspartato/fisiología , Animales , Isquemia Encefálica/fisiopatología , Maleato de Dizocilpina/administración & dosificación , Endotelina-1/administración & dosificación , Antagonistas de Aminoácidos Excitadores/administración & dosificación , Miembro Anterior/efectos de los fármacos , Miembro Anterior/fisiología , Masculino , Microinyecciones/métodos , Fenoles/administración & dosificación , Piperidinas/administración & dosificación , Ratas , Ratas Sprague-DawleyRESUMEN
OBJECTIVE: To determine the effects of 3 α2-adrenergic receptor agonists (α2-ARAs), alone or in combination with butorphanol tartrate, on objective measurements of lameness in horses. ANIMALS: 17 adult polo horses with naturally occurring forelimb or hind limb lameness (or both). PROCEDURES: In a crossover design, each horse received each protocol (saline [0.09% NaCl] solution [2 mL, IV] or xylazine hydrochloride [0.33 mg/kg, IV], detomidine hydrochloride [0.007 mg/kg, IV], or romifidine hydrochloride [0.033 mg/kg, IV] alone or in combination with butorphanol [0.007 mg/kg, IV]) in random order, with a washout period (≥ 7 days) between protocols. Horses were assessed immediately prior to (baseline) and 10, 15, 20, 30, and 40 minutes after administration of each protocol for degree of sedation, mechanical nociceptive threshold (MNT), and objective lameness measurements. RESULTS: Compared with baseline values, sedation scores and MNTs were significantly higher at all evaluated time points following administration of all sedation protocols except xylazine alone; following administration of xylazine alone, sedation scores and MNTs were significantly higher at ≤ 30 minutes and ≤ 20 minutes, respectively. Significant differences in objective forelimb lameness measurements were noted after administration of the 3 α2-ARA-butorphanol combinations. Most significant differences in objective measurements of hind limb lameness were detected after administration of detomidine or romifidine, alone or in combination with butorphanol. CONCLUSIONS AND CLINICAL RELEVANCE: In the study horses, xylazine alone had the least impact on objective lameness measurements. The administration of α2-ARAs, particularly detomidine or romifidine, alone or in combination with butorphanol, resulted in small but significant effects on objective lameness measurements.
Asunto(s)
Agonistas de Receptores Adrenérgicos alfa 2/uso terapéutico , Butorfanol/uso terapéutico , Imidazoles/uso terapéutico , Cojera Animal/tratamiento farmacológico , Xilazina/uso terapéutico , Agonistas de Receptores Adrenérgicos alfa 2/administración & dosificación , Animales , Estudios Cruzados , Quimioterapia Combinada , Femenino , Miembro Anterior/efectos de los fármacos , Marcha/efectos de los fármacos , Caballos , Imidazoles/administración & dosificación , Masculino , Distribución AleatoriaRESUMEN
Thallium (Tl) is a highly toxic metal for human beings; higher amounts found in diverse fluids of pregnant women are associated with low birth weight and preterm birth. However, experimental data concerning their effects on the embryonic development of mammalian organisms are limited. Hence, in the present work, TI(I) acetate of 0, 4.6, 9.2, or 18.5â¯mg/kg body weight were administered by intraperitoneal injection to groups of 10 pregnant CD-1 mice on the 7th gestational day, and animals were sacrificed on day 18 of gestation. The fetuses obtained showed some variations, such as trunk bent over (18.5â¯mg/kg), tail variations (all doses), forelimbs malrotation and hind limbs (all doses). Skeletal examination of the fetuses showed a delay in the ossification of skull bones, ribs, and limbs (all doses). In conclusion, the Intraperitoneal injection of Tl(I) acetate to pregnant mice induced morphological variations and a delay of the fetus ossification.
Asunto(s)
Anomalías Inducidas por Medicamentos/etiología , Talio/toxicidad , Animales , Desarrollo Embrionario , Femenino , Feto/efectos de los fármacos , Miembro Anterior/anomalías , Miembro Anterior/efectos de los fármacos , Miembro Anterior/crecimiento & desarrollo , Miembro Posterior/anomalías , Miembro Posterior/efectos de los fármacos , Miembro Posterior/crecimiento & desarrollo , Masculino , Intercambio Materno-Fetal , Ratones , Osteogénesis/efectos de los fármacos , Embarazo , Costillas/efectos de los fármacos , Costillas/crecimiento & desarrollo , Cráneo/efectos de los fármacos , Cráneo/crecimiento & desarrollo , Cola (estructura animal)/anomalías , Cola (estructura animal)/efectos de los fármacosRESUMEN
We assessed the effect of intake of easily digested carbohydrates for 133 days on quantitative parameters of neuromotorics and cognitive function in Wistar rats and C57Bl/6J mice. Neuromotorics (muscle tone) was assessed in rats and mice by the forelimb muscle force (grip strength) over 4 months. Anxiety was assessed in the elevated plus-maze test and cognitive function (short-term and long-term memory) was evaluated by conditioned passive avoidance response (CPAR) test over 3 months. The mice, in contrast to rats, receiving the diet with easily digested sugars demonstrated suppression of neuromotorics. Anxiety increased with age in female mice, but not in rats, irrespective of the diet. Cognitive function in rats receiving experimental rations did not change significantly in comparison with the control. In mice, consumption of equimolar mixture of fructose and glucose impared short-term, but not long-term memory, in comparison with the group receiving glucose alone. We revealed a small (by 14-17%), but statistically significant increase in the brain weight in mice receiving fructose and sucrose. The study demonstrates sufficient interspecies differences in the influence of carbohydrate rations on neuromotorics and behavioral responses in the in vivo metabolic syndrome model.
Asunto(s)
Cognición/fisiología , Memoria a Largo Plazo/efectos de los fármacos , Memoria a Corto Plazo/efectos de los fármacos , Músculo Esquelético/efectos de los fármacos , Azúcares/farmacología , Factores de Edad , Animales , Encéfalo/efectos de los fármacos , Cognición/efectos de los fármacos , Modelos Animales de Enfermedad , Femenino , Miembro Anterior/efectos de los fármacos , Síndrome Metabólico , Ratones , Ratas , Ratas Wistar , Especificidad de la EspecieRESUMEN
AIMS: To investigate if CIQ, a positive allosteric modulator of N-methyl-d-aspartate receptors (NMDARs) containing GluN2C/D subunits, rescues the loss of long-term potentiation (LTP) and forelimb-use asymmetry in a mouse model of Parkinson's disease (PD). METHODS: We have used electrophysiology in brain slices and the cylinder test to examine the effect of CIQ on glutamatergic synaptic transmission, synaptic plasticity, and forelimb-use in the unilateral 6-hydroxydopamine-lesion mouse model of PD. RESULTS: CIQ, applied in the perfusion solution, reversibly reduced glutamatergic synaptic transmission in the dopamine-depleted striatum and had no effect in the dopamine-intact striatum. LTP, a dopamine- and NMDAR-dependent form of synaptic plasticity, was induced in the dopamine-intact striatum but was lost in the dopamine-depleted striatum. This impaired LTP was restored in the presence of CIQ applied in the perfusion solution. This treatment, however, prevented LTP induction in control slices. In brain slices from mice which received single and chronic intraperitoneal injections of CIQ, LTP was restored in the dopamine-depleted striatum and unaffected in the dopamine-intact striatum. Forelimb-use asymmetry, a test which assesses deficits in paw usage in the unilateral lesion model of PD, was reversed by systemic chronic treatment with CIQ. CONCLUSION: A positive allosteric modulator of GluN2C/D-containing NMDARs rescues LTP and forelimb-use asymmetry in a mouse model of PD. This study proposes GluN2D as a potential candidate for therapeutic intervention in PD.
Asunto(s)
Antiparkinsonianos/farmacología , Bencimidazoles/farmacología , Cuerpo Estriado/efectos de los fármacos , Fármacos actuantes sobre Aminoácidos Excitadores/farmacología , Potenciación a Largo Plazo/efectos de los fármacos , Trastornos Parkinsonianos/tratamiento farmacológico , Regulación Alostérica , Animales , Cuerpo Estriado/metabolismo , Miembro Anterior/efectos de los fármacos , Miembro Anterior/fisiopatología , Potenciación a Largo Plazo/fisiología , Masculino , Ratones Endogámicos C57BL , Actividad Motora/efectos de los fármacos , Actividad Motora/fisiología , Oxidopamina , Trastornos Parkinsonianos/metabolismo , Receptores de N-Metil-D-Aspartato/metabolismo , Transmisión Sináptica/efectos de los fármacos , Transmisión Sináptica/fisiología , Técnicas de Cultivo de TejidosRESUMEN
OBJECTIVE To assess the effects of sedation on results of acoustoelastography of the superficial digital flexor tendons (SDFTs) in clinically normal horses. ANIMALS 27 clinically normal horses. PROCEDURES For each horse, the pathology index (PI) for the SDFT of each thoracic limb was determined by use of acoustoelastography at 4 locations (5, 10, 15, and 20 cm distal to the accessory carpal bone). Horses were evaluated before and after they were sedated with a combination of detomidine hydrochloride (0.01 mg/kg, IV) and butorphanol tartrate (0.01 mg/kg, IV). A repeated-measures ANOVA was used for statistical analysis. RESULTS Overall, the PI was lower after sedation than before sedation. In addition, the PI was lower at more distal locations than at more proximal locations. There was not a significant effect of limb (left or right). Differences among individual horses accounted for the largest variance effect. CONCLUSIONS AND CLINICAL RELEVANCE Sedation with detomidine and butorphanol facilitated acoustoelastography; however, it decreased the SDFT PI in clinically normal horses and should be used consistently in prospective studies. Variance associated with each individual horse in the sample population had the greatest effect on the PI.
Asunto(s)
Butorfanol/farmacología , Diagnóstico por Imagen de Elasticidad/veterinaria , Caballos , Hipnóticos y Sedantes/farmacología , Imidazoles/farmacología , Tendones/efectos de los fármacos , Tendones/diagnóstico por imagen , Animales , Diagnóstico por Imagen de Elasticidad/métodos , Femenino , Miembro Anterior/efectos de los fármacos , Imidazoles/administración & dosificación , Masculino , Estudios ProspectivosRESUMEN
Cyclin-dependent kinase 5 (Cdk5) is recognized as a unique member among other Cdks due to its versatile roles in many biochemical processes in the nervous system. The proper development of neuronal dendrites is required for the formation of complex neural networks providing the physiological basis of various neuronal functions. We previously reported that sparse dendrites were observed on cultured Cdk5-null Purkinje cells and Purkinje cells in Wnt1cre -mediated Cdk5 conditional knockout (KO) mice. In the present study, we generated L7cre -mediated p35; p39 double KO (L7cre -p35f/f ; p39-/- ) mice whose Cdk5 activity was eliminated specifically in Purkinje cells of the developing cerebellum. Consequently, these mice exhibited defective Purkinje cell migration, motor coordination deficiency and a Purkinje dendritic abnormality similar to what we have observed before, suggesting that dendritic growth of Purkinje cells was cell-autonomous in vivo. We found that mixed and overlay cultures of WT cerebellar cells rescued the dendritic deficits in Cdk5-null Purkinje cells, however, indicating that Purkinje cell dendritic development was also supported by non-cell-autonomous factors. We then again rescued these abnormalities in vitro by applying exogenous brain-derived neurotrophic factor (BDNF). Based on the results from culture experiments, we attempted to rescue the developmental defects of Purkinje cells in L7cre -p35f/f ; p39-/- mice by using a TrkB agonist. We observed partial rescue of morphological defects of dendritic structures of Purkinje cells. These results suggest that Cdk5 activity is required for Purkinje cell dendritic growth in cell-autonomous and non-cell-autonomous manners. © 2017 Wiley Periodicals, Inc. Develop Neurobiol 77: 1175-1187, 2017.
Asunto(s)
Quinasa 5 Dependiente de la Ciclina/metabolismo , Dendritas/enzimología , Proyección Neuronal/fisiología , Células de Purkinje/enzimología , Animales , Factor Neurotrófico Derivado del Encéfalo/metabolismo , Calbindinas/metabolismo , Células Cultivadas , Cerebelo/efectos de los fármacos , Cerebelo/enzimología , Cerebelo/crecimiento & desarrollo , Cerebelo/patología , Dendritas/efectos de los fármacos , Dendritas/patología , Miembro Anterior/efectos de los fármacos , Miembro Anterior/fisiopatología , Inmunohistoquímica , Masculino , Ratones Endogámicos C57BL , Ratones Noqueados , Actividad Motora/efectos de los fármacos , Actividad Motora/fisiología , Fuerza Muscular/efectos de los fármacos , Fuerza Muscular/fisiología , Proyección Neuronal/efectos de los fármacos , Células de Purkinje/efectos de los fármacos , Células de Purkinje/patología , Receptor trkB/agonistas , Receptor trkB/metabolismo , Prueba de Desempeño de Rotación con Aceleración ConstanteRESUMEN
BACKGROUND: 4-Aminopyridine (4-AP) is a Food and Drug Administration-approved drug to improve motor function in people with multiple sclerosis. Preliminary results suggest the drug may act on intact neural circuits and not just on demyelinated ones. OBJECTIVE: To determine if 4-AP at clinically relevant levels alters the excitability of intact motor circuits. METHODS: In anesthetized rats, electrodes were placed over motor cortex and the dorsal cervical spinal cord for electrical stimulation, and electromyogram electrodes were inserted into biceps muscle to measure responses. The motor responses to brain and spinal cord stimulation were measured before and for 5 hours after 4-AP administration both in uninjured rats and rats with a cut lesion of the pyramidal tract. Blood was collected at the same time as electrophysiology to determine drug plasma concentration with a goal of 20 to 100 ng/mL. RESULTS: We first determined that a bolus infusion of 0.32 mg/kg 4-AP was optimal: it produced on average 61.5 ± 1.8 ng/mL over the 5 hours after infusion. This dose of 4-AP increased responses to spinal cord stimulation by 1.3-fold in uninjured rats and 3-fold in rats with pyramidal tract lesion. Responses to cortical stimulation also increased by 2-fold in uninjured rats and up to 4-fold in the injured. CONCLUSION: Clinically relevant levels of 4-AP strongly augment physiological responses in intact circuits, an effect that was more robust after partial injury, demonstrating its broad potential in treating central nervous system injuries.
Asunto(s)
4-Aminopiridina/farmacología , Fármacos del Sistema Nervioso Central/farmacología , Médula Cervical/efectos de los fármacos , Corteza Motora/efectos de los fármacos , Tractos Piramidales/efectos de los fármacos , Traumatismos de la Médula Espinal/tratamiento farmacológico , 4-Aminopiridina/sangre , 4-Aminopiridina/farmacocinética , Animales , Fármacos del Sistema Nervioso Central/sangre , Fármacos del Sistema Nervioso Central/farmacocinética , Médula Cervical/lesiones , Médula Cervical/fisiología , Médula Cervical/fisiopatología , Evaluación Preclínica de Medicamentos , Estimulación Eléctrica , Electromiografía , Potenciales Evocados Motores/efectos de los fármacos , Potenciales Evocados Motores/fisiología , Femenino , Miembro Anterior/efectos de los fármacos , Miembro Anterior/fisiología , Miembro Anterior/fisiopatología , Microelectrodos , Corteza Motora/fisiología , Corteza Motora/fisiopatología , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/fisiología , Músculo Esquelético/fisiopatología , Tractos Piramidales/lesiones , Tractos Piramidales/fisiología , Tractos Piramidales/fisiopatología , Distribución Aleatoria , Ratas Sprague-Dawley , Traumatismos de la Médula Espinal/fisiopatologíaRESUMEN
Immobilization, bed rest, or sedentary lifestyle, are known to induce a profound impairment in sensorimotor performance. These alterations are due to a combination of peripheral and central factors. Previous data conducted on a rat model of disuse (hindlimb unloading, HU) have shown a profound reorganization of motor cortex and an impairment of motor performance. Recently, our interest was turned towards the role of insulin-like growth factor 1 (IGF-1) in cerebral plasticity since this growth factor is considered as the mediator of beneficial effects of exercise on the central nervous system, and its cortical level is decreased after a 14-day period of HU. In the present study, we attempted to determine whether a chronic subdural administration of IGF-1 in HU rats could prevent deleterious effects of HU on the motor cortex and on motor activity. We demonstrated that HU induces a shrinkage of hindlimb cortical representation and an increase in current threshold to elicit a movement. Administration of IGF-1 in HU rats partially reversed these changes. The functional evaluation revealed that IGF-1 prevents the decrease in spontaneous activity found in HU rats and the changes in hip kinematics during overground locomotion, but had no effect of challenged locomotion (ladder rung walking test). Taken together, these data clearly indicate the implication of IGF-1 in cortical plastic mechanisms and in behavioral alteration induced by a decreased in sensorimotor activity.
Asunto(s)
Suspensión Trasera/efectos adversos , Factor I del Crecimiento Similar a la Insulina/uso terapéutico , Corteza Motora/efectos de los fármacos , Corteza Motora/fisiología , Trastornos Motores/tratamiento farmacológico , Análisis de Varianza , Animales , Tobillo/inervación , Fenómenos Biomecánicos , Sistemas de Liberación de Medicamentos , Miembro Anterior/efectos de los fármacos , Miembro Anterior/fisiología , Miembro Posterior/efectos de los fármacos , Miembro Posterior/fisiología , Cadera/inervación , Locomoción/efectos de los fármacos , Locomoción/fisiología , Masculino , Proteínas de la Membrana , Trastornos Motores/etiología , Proteínas de Unión a Fosfato , Desempeño Psicomotor/efectos de los fármacos , Ratas , Ratas WistarRESUMEN
Implantation of electrodes or cannulae into the brain is accompanied by a tissue response referred to as foreign body response. Adenosine triphosphate (ATP) is one of the signalling molecules released by injured cells which mediate the chemoattraction of microglial cells. The constitutive release of pro-inflammatory and cytotoxic substances by microglial cells in chronic implants exacerbates neuronal cell death and the immune response. This study aimed to interfere with the initial events of the foreign body response in order to mitigate neurotoxicity and inflammation. For this purpose, the ATP-hydrolysing enzyme apyrase and the antibiotic minocycline with a broad range of anti-inflammatory, anti-apoptotic and glutamate-antagonist properties were locally infused during cannula implantation in the caudal forelimb area of the motor cortex in Lister Hooded rats. The rats' motor performance was assessed in a skilled reaching task and the distribution of neurons and glial cells in the vicinity of the implant was examined 2 and 6 weeks post-implantation. Apyrase as well as minocycline increased the number of surviving neurons and reduced microglial activation. Moreover, minocycline improved the motor performance and, additionally, caused a temporary reduction in astrogliosis, suggesting it as a possible therapeutic candidate to improve the biocompatibility of chronic brain implants.
Asunto(s)
Apirasa/farmacología , Encéfalo/efectos de los fármacos , Cánula/efectos adversos , Reacción a Cuerpo Extraño/prevención & control , Minociclina/farmacología , Fármacos Neuroprotectores/farmacología , Animales , Encéfalo/inmunología , Encéfalo/patología , Reacción a Cuerpo Extraño/inmunología , Reacción a Cuerpo Extraño/patología , Miembro Anterior/efectos de los fármacos , Miembro Anterior/inmunología , Miembro Anterior/patología , Masculino , Microglía/efectos de los fármacos , Microglía/inmunología , Microglía/patología , Actividad Motora/efectos de los fármacos , Corteza Motora/efectos de los fármacos , Corteza Motora/inmunología , Corteza Motora/patología , Neuronas/efectos de los fármacos , Neuronas/inmunología , Neuronas/patología , Ratas EndogámicasRESUMEN
Epidemiological and experimental studies have demonstrated that excessive exposure to fluoride induced neurodevelopmental toxicity both in humans and animals. Taurine is a free intracellular ß-amino acid with antioxidant and neuroprotective properties. The present study investigated the neuroprotective mechanism of taurine by evaluating the biochemical and behavioral characteristics in rats exposed to sodium fluoride (NaF) singly in drinking water at 15 mg/L alone or orally co-administered by gavage with taurine at 100 and 200 mg/kg body weight for 45 consecutive days. Locomotor behavior was assessed using video-tracking software during a 10-min trial in a novel environment while the brain structures namely the hypothalamus, cerebrum and cerebellum of the rats were processed for biochemical determinations. Results showed that taurine administration prevented NaF-induced locomotor and motor deficits namely decrease in total distance travelled, total body rotation, maximum speed, absolute turn angle along with weak forelimb grip, increased incidence of fecal pellets and time of grooming, immobility and negative geotaxis. The taurine mediated enhancement of the exploratory profiles of NaF-exposed rats was supported by track and occupancy plot analyses. Moreover, taurine prevented NaF-induced increase in hydrogen peroxide and lipid peroxidation levels but increased acetylcholinesterase and the antioxidant enzymes activities in the hypothalamus, cerebrum and cerebellum of the rats. Collectively, taurine protected against NaF-induced neurotoxicity via mechanisms involving the restoration of acetylcholinesterase activity and antioxidant status with concomitant inhibition of lipid peroxidation in the brain of rats.
Asunto(s)
Conducta Animal/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Fluoruro de Sodio/farmacología , Taurina/farmacología , Acetilcolinesterasa/metabolismo , Animales , Antioxidantes/metabolismo , Encéfalo/efectos de los fármacos , Encéfalo/patología , Catalasa/metabolismo , Conducta Exploratoria/efectos de los fármacos , Heces , Miembro Anterior/efectos de los fármacos , Miembro Anterior/fisiología , Aseo Animal/efectos de los fármacos , Peróxido de Hidrógeno/metabolismo , Masculino , Malondialdehído/metabolismo , Actividad Motora/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Ratas Wistar , Superóxido Dismutasa/metabolismoRESUMEN
A deeper understanding of post-stroke plasticity is critical to devise more effective pharmacological and rehabilitative treatments. The GABAergic system is one of the key modulators of neuronal plasticity, and plays an important role in the control of "critical periods" during brain development. Here, we report a key role for GABAergic inhibition in functional restoration following ischemia in the adult mouse forelimb motor cortex. After stroke, the majority of cortical sites in peri-infarct areas evoked simultaneous movements of forelimb, hindlimb and tail, consistent with a loss of inhibitory signalling. Accordingly, we found a delayed decrease in several GABAergic markers that accompanied cortical reorganization. To test whether reductions in GABAergic signalling were causally involved in motor improvements, we treated animals during an early post-stroke period with a benzodiazepine inverse agonist, which impairs GABAA receptor function. We found that hampering GABAA signalling led to significant restoration of function in general motor tests (i.e., gridwalk and pellet reaching tasks), with no significant impact on the kinematics of reaching movements. Improvements were persistent as they remained detectable about three weeks after treatment. These data demonstrate a key role for GABAergic inhibition in limiting motor improvements after cortical stroke.
Asunto(s)
Isquemia Encefálica/tratamiento farmacológico , Miembro Anterior/fisiopatología , Agonistas de Receptores de GABA-A/administración & dosificación , Actividad Motora/efectos de los fármacos , Animales , Fenómenos Biomecánicos/efectos de los fármacos , Isquemia Encefálica/metabolismo , Isquemia Encefálica/fisiopatología , Modelos Animales de Enfermedad , Miembro Anterior/efectos de los fármacos , Miembro Anterior/metabolismo , Agonistas de Receptores de GABA-A/farmacología , Humanos , Masculino , Ratones , Plasticidad Neuronal/efectos de los fármacos , Recuperación de la Función/efectos de los fármacos , Transducción de Señal/efectos de los fármacosRESUMEN
This research investigated the effects of neem oil on mortality, survival and malformations of the non-target stink bug predator, Podisus nigrispinus. Neurotoxic and growth inhibitor insecticides were used to compare the lethal and sublethal effects from neem oil on this predator. Six concentrations of neem oil were topically applied onto nymphs and adults of this predator. The mortality rates of third, fourth, and fifth instar nymphs increased with increasing neem oil concentrations, suggesting low toxicity to P. nigrispinus nymphs. Mortality of adults was low, but with sublethal effects of neem products on this predator. The developmental rate of P. nigrispinus decreased with increasing neem oil concentrations. Longevity of fourth instar nymphs varied from 3.74 to 3.05 d, fifth instar from 5.94 to 4.07 d and adult from 16.5 and 15.7 d with 0.5 and 50% neem doses. Podisus nigrispinus presented malformations and increase with neem oil concentrations. The main malformations occur in wings, scutellum and legs of this predator. The neem oil at high and sub lethal doses cause mortality, inhibits growth and survival and results in anomalies on wings and legs of the non-traget predator P. nigrispinus indicating that its use associated with biological control should be carefully evaluated.
Asunto(s)
Glicéridos/farmacología , Heterópteros/efectos de los fármacos , Longevidad/efectos de los fármacos , Ninfa/efectos de los fármacos , Terpenos/farmacología , Alas de Animales/efectos de los fármacos , Animales , Relación Dosis-Respuesta a Droga , Femenino , Miembro Anterior/anomalías , Miembro Anterior/efectos de los fármacos , Heterópteros/crecimiento & desarrollo , Heterópteros/fisiología , Miembro Posterior/anomalías , Miembro Posterior/efectos de los fármacos , Insecticidas/farmacología , Longevidad/fisiología , Masculino , Ninfa/crecimiento & desarrollo , Ninfa/fisiología , Conducta Predatoria/efectos de los fármacos , Alas de Animales/anomalíasRESUMEN
Metabotropic glutamate receptor 4 (mGlu4) is emerging as a potential therapeutic target for numerous central nervous system indications, including Parkinson's disease (PD). As the glutamate binding sites among the eight mGlu receptors are highly conserved, modulation of receptor activity via allosteric sites within the receptor transmembrane domains using positive and negative allosteric modulators (PAMs and NAMs, respectively) has become a common strategy. We and others have used PAMs targeting mGlu4 to show that potentiation of receptor signaling induces antiparkinsonian activity in a variety of PD animal models, including haloperidol-induced catalepsy and 6-hydroxydopamine-induced lesion. Recently, mGlu4 has been reported to form heteromeric complexes with other mGlu receptor subtypes, such as mGlu2, and the resulting heteromer exhibits a distinct pharmacological profile in response to allosteric modulators. For example, some mGlu4 PAMs do not appear to potentiate glutamate activity when mGlu2 and mGlu4 are coexpressed, whereas other compounds potentiate mGlu4 responses regardless of mGlu2 coexpression. We report here the discovery and characterization of VU0418506, a novel mGlu4 PAM with activity in rodent PD models. Using pharmacological approaches and Complemented Donor-Acceptor resonance energy transfer (CODA-RET) technology, we find that VU0418506 does not potentiate agonist-induced activity when mGlu2 and mGlu4 are heterodimerized, suggesting that the antiparkinsonian action of mGlu4 PAMs can be induced by compounds without activity at mGlu2/4 heteromers.
Asunto(s)
Antiparkinsonianos/síntesis química , Antiparkinsonianos/farmacología , Enfermedad de Parkinson/tratamiento farmacológico , Receptores de Glutamato Metabotrópico/metabolismo , Regulación Alostérica/efectos de los fármacos , Animales , Antiparkinsonianos/química , Antipsicóticos/farmacología , Apomorfina/farmacología , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Catalepsia/inducido químicamente , Catalepsia/tratamiento farmacológico , Modelos Animales de Enfermedad , Agonistas de Dopamina/farmacología , Miembro Anterior/efectos de los fármacos , Miembro Anterior/fisiopatología , Ácido Glutámico/farmacología , Células HEK293 , Haloperidol/farmacología , Humanos , Oxidopamina/toxicidad , Enfermedad de Parkinson/etiología , Enfermedad de Parkinson/patología , Ratas , Ratas Sprague-Dawley , Receptores de Glutamato Metabotrópico/genética , TransfecciónRESUMEN
Neuroplasticity and reorganization of brain motor networks are thought to enable recovery of motor function after ischemic stroke. Especially in the cortex surrounding the ischemic scar (i.e., peri-infarct cortex), evidence for lasting reorganization has been found at the level of neurons and networks. This reorganization depends on expression of specific genes and subsequent protein synthesis. To test the functional relevance of the peri-infarct cortex for recovery we assessed the effect of protein synthesis inhibition within this region after experimental stroke. Long-Evans rats were trained to perform a skilled-reaching task (SRT) until they reached plateau performance. A photothrombotic stroke was induced in the forelimb representation of the primary motor cortex (M1) contralateral to the trained paw. The SRT was re-trained after stroke while the protein synthesis inhibitor anisomycin (ANI) or saline were injected into the peri-infarct cortex through implanted cannulas. ANI injections reduced protein synthesis within the peri-infarct cortex by 69% and significantly impaired recovery of reaching performance through re-training. Improvement of motor performance within a single training session remained intact, while improvement between training sessions was impaired. ANI injections did not affect infarct size. Thus, protein synthesis inhibition within the peri-infarct cortex impairs recovery of motor deficits after ischemic stroke by interfering with consolidation of motor memory between training sessions but not short-term improvements within one session.